TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
US7517886B2
(en)
|
2002-07-29 |
2009-04-14 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
WO2004056807A1
(fr)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Derives de pyrimidine destines au traitement de la croissance cellulaire anormale
|
GB0305929D0
(en)
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
CN102358738A
(zh)
|
2003-07-30 |
2012-02-22 |
里格尔药品股份有限公司 |
2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
|
PL1660458T3
(pl)
*
|
2003-08-15 |
2012-07-31 |
Novartis Ag |
2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
|
BRPI0510980A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina para o tratamento do crescimento anormal de células
|
BRPI0511132A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina e composição farmacêutica compreendendo os mesmos
|
WO2005111016A1
(fr)
|
2004-05-14 |
2005-11-24 |
Pfizer Products Inc. |
Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale
|
WO2006004776A1
(fr)
|
2004-06-29 |
2006-01-12 |
Rigel Pharmaceuticals, Inc. |
Composés de 4-pyrimidineamine et leurs utilisations en tant qu’agent anti-prolifération
|
WO2006012502A2
(fr)
*
|
2004-07-23 |
2006-02-02 |
Rigel Pharmaceuticals, Inc. |
Preparation d'agents therapeutiques a petites molecules insolubles dans des excipients lipidiques
|
GB0419161D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
GB0419160D0
(en)
*
|
2004-08-27 |
2004-09-29 |
Novartis Ag |
Organic compounds
|
AU2005289426A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
CA2584295C
(fr)
|
2004-11-24 |
2014-08-26 |
Rigel Pharmaceuticals, Inc. |
Composes de spiro-2, 4-pyrimidinediamine et leurs utilisations
|
DE602006010979D1
(de)
|
2005-01-19 |
2010-01-21 |
Rigel Pharmaceuticals Inc |
Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
US20060247263A1
(en)
*
|
2005-04-19 |
2006-11-02 |
Amgen Inc. |
Substituted heterocyclic compounds and methods of use
|
KR100602320B1
(ko)
*
|
2005-05-03 |
2006-07-18 |
주식회사 하이닉스반도체 |
프로그램 속도가 균일한 비휘발성 메모리 소자
|
WO2006133426A2
(fr)
*
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions et procedes d'inhibition de la voie jak
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8604042B2
(en)
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
JP2009518443A
(ja)
|
2005-12-06 |
2009-05-07 |
リゲル ファーマシューティカルズ インコーポレーティッド |
脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
|
AU2006327871A1
(en)
|
2005-12-21 |
2007-06-28 |
Pfizer Products Inc. |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
TW200736232A
(en)
*
|
2006-01-26 |
2007-10-01 |
Astrazeneca Ab |
Pyrimidine derivatives
|
CA2642229C
(fr)
|
2006-02-24 |
2015-05-12 |
Rigel Pharmaceuticals, Inc. |
Compositions et methodes destinees a l'inhibition de la voie jak
|
GB2451594A
(en)
*
|
2006-03-15 |
2009-02-04 |
Csir |
Modulation of phosphoryl transferase activity of glutamine synthetase
|
CN101438288A
(zh)
*
|
2006-03-15 |
2009-05-20 |
Csir公司 |
谷氨酰胺合成酶的磷酰基转移酶活性的调节
|
WO2008049123A2
(fr)
*
|
2006-10-19 |
2008-04-24 |
Rigel Pharmaceuticals, Inc. |
Compositions et procédés pour l'inhibition de la voie jak
|
TWI432427B
(zh)
|
2006-10-23 |
2014-04-01 |
Cephalon Inc |
作為ALK及c-MET抑制劑之2,4-二胺基嘧啶之融合雙環衍生物
|
EP3012249A1
(fr)
|
2006-12-08 |
2016-04-27 |
Novartis AG |
Composes et compostions inhibtant la proteine kinase
|
EP1939185A1
(fr)
*
|
2006-12-20 |
2008-07-02 |
Bayer Schering Pharma Aktiengesellschaft |
Nouveaux hetaryl-phénylènediamine-pyrimidines en tant qu'inhibiteurs de protéine kinase pour le traitement du cancer
|
MX2009006454A
(es)
|
2006-12-22 |
2009-06-26 |
Hoffmann La Roche |
Derivados de espiro-piperidina.
|
FR2911137B1
(fr)
*
|
2007-01-05 |
2009-02-20 |
Sanofi Aventis Sa |
Nouveaux derives de 2,4-dianilinopyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
|
BRPI0807897A2
(pt)
*
|
2007-03-01 |
2014-06-17 |
Supergen Inc |
Derivados de pirimidina-2,4-diamina e seus usos como inibidores de jak2 quinase.
|
EP1969929A1
(fr)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
Phénylamidine substituée et son utilisation en tant que fongicide
|
AU2014201847B2
(en)
*
|
2007-04-18 |
2015-12-24 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
AU2016201820B2
(en)
*
|
2007-04-18 |
2018-03-08 |
Pfizer Products Inc. |
Sulfonyl amide derivatives for the treatment of abnormal cell growth
|
MX2009011090A
(es)
*
|
2007-04-18 |
2009-11-02 |
Pfizer Prod Inc |
Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
|
WO2009071535A1
(fr)
*
|
2007-12-03 |
2009-06-11 |
Boehringer Ingelheim International Gmbh |
Nouveaux composés
|
AU2009203773B2
(en)
|
2008-01-11 |
2013-04-18 |
F. Hoffmann-La Roche Ag |
Modulators for amyloid beta
|
CN101952275B
(zh)
|
2008-02-22 |
2014-06-18 |
弗·哈夫曼-拉罗切有限公司 |
β-淀粉样蛋白的调节剂
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
NZ589315A
(en)
|
2008-04-16 |
2012-11-30 |
Portola Pharm Inc |
2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
|
KR20170051521A
(ko)
|
2008-04-16 |
2017-05-11 |
포톨라 파마슈티컬스, 인코포레이티드 |
syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드
|
EP2271631B1
(fr)
|
2008-04-22 |
2018-07-04 |
Portola Pharmaceuticals, Inc. |
Inhibiteurs de protéines kinases
|
CA2723961C
(fr)
|
2008-05-21 |
2017-03-21 |
Ariad Pharmaceuticals, Inc. |
Derives phosphores servant d'inhibiteurs de kinase
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
DE102008049323A1
(de)
*
|
2008-09-29 |
2010-04-01 |
Henkel Ag & Co. Kgaa |
Neue Entwicklerkomponenten
|
WO2010040661A1
(fr)
|
2008-10-09 |
2010-04-15 |
F. Hoffmann-La Roche Ag |
Modulateurs pour l'amyloïde bêta
|
EP2355817A1
(fr)
|
2008-11-10 |
2011-08-17 |
F. Hoffmann-La Roche AG |
Modulateurs de la gamma secrétase hétérocyclique
|
WO2010083207A2
(fr)
*
|
2009-01-15 |
2010-07-22 |
Rigel Pharmaceuticals, Inc. |
Inhibiteurs de la protéine kinase c et leurs utilisations
|
JP5539518B2
(ja)
|
2009-08-14 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製
|
US8933227B2
(en)
|
2009-08-14 |
2015-01-13 |
Boehringer Ingelheim International Gmbh |
Selective synthesis of functionalized pyrimidines
|
CA2784807C
(fr)
|
2009-12-29 |
2021-12-14 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de kinase raf de type ii
|
US8486967B2
(en)
|
2010-02-17 |
2013-07-16 |
Hoffmann-La Roche Inc. |
Heteroaryl substituted piperidines
|
AU2011254550B2
(en)
|
2010-05-21 |
2013-11-07 |
Noviga Research Ab |
Novel pyrimidine derivatives
|
EP2635557A2
(fr)
|
2010-11-01 |
2013-09-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides en tant que modulateurs des jak kinases
|
US8846928B2
(en)
|
2010-11-01 |
2014-09-30 |
Portola Pharmaceuticals, Inc. |
Benzamides and nicotinamides as Syk modulators
|
US20130317029A1
(en)
|
2010-11-01 |
2013-11-28 |
Portola Pharmaceuticals, Inc. |
Oxypyrimidines as syk modulators
|
WO2012060847A1
(fr)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions et procédés de traitement de la myélofibrose
|
CA2830129C
(fr)
|
2011-03-24 |
2016-07-19 |
Chemilia Ab |
Nouveaux derives de pyrimidine
|
US9249124B2
(en)
|
2011-03-30 |
2016-02-02 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Aurora kinase inhibitors and methods of making and using thereof
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
WO2013074986A1
(fr)
*
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de la kinase c-jun-n-terminale (jnk)
|
IN2014CN04065A
(fr)
|
2011-11-23 |
2015-09-04 |
Portola Pharm Inc |
|
EP2606884A1
(fr)
*
|
2011-12-21 |
2013-06-26 |
Ecole Polytechnique Fédérale de Lausanne (EPFL) |
Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement des cancers
|
WO2013169401A1
(fr)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Composés pour inhiber la prolifération cellulaire dans les cancers induits par l'egfr
|
KR101446742B1
(ko)
*
|
2012-08-10 |
2014-10-01 |
한국화학연구원 |
N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
WO2014058921A2
(fr)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Inhibiteurs substitués de pyrimidinyl kinase
|
WO2014063061A1
(fr)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Petites molécules marquées de façon hydrophobe en tant qu'inducteurs de la dégradation de protéine
|
US10202356B2
(en)
*
|
2013-03-14 |
2019-02-12 |
Tolero Pharmaceuticals, Inc. |
JAK2 and ALK2 inhibitors and methods for their use
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
JP6491202B2
(ja)
|
2013-10-18 |
2019-03-27 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
サイクリン依存性キナーゼ7(cdk7)の多環阻害剤
|
ES2676734T3
(es)
|
2013-10-18 |
2018-07-24 |
Syros Pharmaceuticals, Inc. |
Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas
|
WO2016022460A1
(fr)
|
2014-08-03 |
2016-02-11 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Puissants doubles inhibiteurs de brd4 et de kinase à utiliser en tant qu'agents thérapeutiques anticancéreux
|
WO2016105528A2
(fr)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
|
CA2978518C
(fr)
|
2015-03-27 |
2023-11-21 |
Nathanael S. Gray |
Inhibiteurs de kinases cycline-dependantes
|
EP4019515A1
(fr)
|
2015-09-09 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Inhibiteurs de kinases cycline-dépendantes
|
WO2017066428A1
(fr)
|
2015-10-13 |
2017-04-20 |
H. Lee Moffitt Cancer Center & Research Institute, Inc. |
Inhibiteurs de brd4-kinase à utiliser en tant qu'agents thérapeutiques anticancéreux
|
IL270869B2
(en)
*
|
2017-05-26 |
2023-09-01 |
Cancer Research Tech Ltd |
Benzimidazolone derivative inhibitors of bcl6
|
CN117343049A
(zh)
|
2017-06-30 |
2024-01-05 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
WO2019000682A1
(fr)
|
2017-06-30 |
2019-01-03 |
北京泰德制药股份有限公司 |
Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications
|
JP7039802B2
(ja)
|
2017-06-30 |
2022-03-23 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Rho-関連プロテインキナーゼ阻害剤、rho-関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
|
CN109776522B
(zh)
*
|
2017-10-30 |
2020-12-29 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
MX2020010437A
(es)
|
2018-04-05 |
2021-01-29 |
Sumitomo Pharma Oncology Inc |
Inhibidores de axl cinasa y uso de los mismos.
|
US20210113562A1
(en)
|
2018-04-13 |
2021-04-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
|
WO2020006724A1
(fr)
*
|
2018-07-05 |
2020-01-09 |
清华大学 |
Composé de dégradation ciblée de protéine fak et utilisation associée
|
CA3103995A1
(fr)
|
2018-07-26 |
2020-01-30 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci
|
CN111362922A
(zh)
*
|
2018-12-26 |
2020-07-03 |
上海喆邺生物科技有限公司 |
2,4-二氨基嘧啶衍生物及其用途
|
EP3924351A4
(fr)
|
2019-02-12 |
2022-12-21 |
Sumitomo Pharma Oncology, Inc. |
Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
|
CN114105887B
(zh)
*
|
2021-09-16 |
2023-12-01 |
沈阳药科大学 |
一种氨基嘧啶衍生物及其制备方法和用途
|